The global 3D cell culture market is anticipated to reach USD 1.69 billion by 2024, according to a new report by Grand View Research, Inc. Potential of this technology to replace and reduce the usage of animal models for histological analysis and biochemical assays is expected to fuel demand for 3D cell culture products thus driving growth in the coming years.
Advent of technology with respect to spheroid formation and matured assay methods, is expected to boost the emergence of 3D optimized assays, kits, and protocols, in turn, expediting the entire research process. In addition, the scope of three-dimensional (3D) cell culturing experiments for evaluation of drug moiety is anticipated to grow owing to advantages associated with its usage. These advantages include increased cell to extra cellular matrix (ECM) as well as intercellular interactions, variation in the proliferation zones, ease for analyzing impact of site-specific stromal tissue components in the tumor microenvironment.
Research initiatives carried out to develop multidimensional cultures that offer compatibility with automated lab equipment and suitability for HTS feature in order to facilitate high content screening assay, signaling, and migration are expected to fuel the growth of this vertical through to 2024.
View summary of this report @ http://www.grandviewresearch.com/industry-analysis/3d-cell-culture-market
Further key findings from the report suggest:
·
Scaffold-based technique accounted for the
revenue share of over 40% because of the potential these possess for the
recreation of structural and physical environment of a living tissue.
Availability of choice for the material and structure of the scaffold for
different in vitro applications is supportive for the estimated revenue share
of this segment. Hydrogel or ECM and solid scaffolds are estimated to capture a
comparatively sizable share of the revenue, attributed to the presence of
different products in this segment.
·
Spheroid development techniques are estimated to
contribute significantly in increasing the revenue share of scaffold-free technology.
These enable multicellular arrangement, thus making them an influential tool
for a range of applications, particularly in cancer and stem cell
research.Oncology is estimated to account for the dominant share in 2015 owing
to the presence of higher incidence rate of cancers coupled with phenotypic
heterogeneity achieved using 3D culturing. Stem cell research is anticipated to
witness lucrative growth in the coming years as a consequence of the upcoming
projects in this segment for development of effective therapies.
·
Key end users for this technology are pharma
& biotech entities, research laboratories and institutes. Pharma &
biotech entities accounted for the largest share of the revenue in 2015 owing
to the high usage of technology in different steps of drug discovery which
include target validation, lead optimization, penetration studies, and safety
assessment or toxicity screening.
·
North America dominated the next generation
sequencing data analysis market with a share of over 40% as a result of the
presence of several organizations operating in this region. Moreover, the
significant number of R&D projects carried out in institutes is resulting
in the high demand, affecting the revenue growth significantly.
·
However, Asia Pacific is expected to witness
substantially high growth through to 2024, which is attributable to the rise in
number of research grants for drug development and tissue engineering projects
in the developing economies of this region. Furthermore, positive R&D
outcomes encouraging the incorporation of three dimensional cultures in
regenerative medicine is expected to impact this sector with potential
opportunities for growth.
·
The market is fragmented in nature and includes
established as well as emerging players These entities include 3D Biomatrix,
Corning Inc, Nano3D Biosciences, Merck, Becton Dickinson and Company, Thermo
Fisher Scientific, InSphero AG, Lonza Group, Tecan, 3D Biotek LLC, VWR
International, LLC, and Global Cell Solutions, Inc.
·
These companies are involved in collaborations
and co-marketing agreements for enhancement of product portfolio as well as
global presence. For instance, Tecan and CellSpring entered into collaboration
for automation of the 3D Bloom platform on a Freedom EVO workstation.
Browse
more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/biotechnology
Grand View Research has segmented 3D cell culture market on the basis of technology, application, end use and region:
Global 3D Cell Culture Outlook, by Technology (Revenue, USD Million, 2013 - 2024)
·
Scaffold Based
o
Hydrogels
o
Polymeric Scaffolds
o
Micro - patterned Surface Microplates
·
Scaffold Free
o
Hanging Drop Microplates
o
Spheroid Microplates with ULA coating
o
Microfluidic 3D Cell Culture
o
Magnetic Levitations & 3D Bioprinting
·
Bioreactors
Global 3D Cell CultureOutlook, by Application (Revenue, USD Million,
2013 - 2024)
·
Cancer
·
Tissue Engineering & Immunohistochemistry
·
Drug Development
·
Stem Cell Research
·
Others
Global 3D Cell CultureOutlook, by End - use, (Revenue, USD Million,
2013 - 2024)
·
Biotechnology and Pharmaceutical Industries
·
Research Laboratories and Institutes
·
Hospitals and Diagnostic Centers
·
Others
Global 3D Cell Culture Market, Regional Outlook (Revenue, USD
Million, 2013 - 2024)
·
North America
o
U.S.
o
Canada
·
Europe
o
Germany
o
UK
·
Asia Pacific
o
China
o
Japan
·
Latin America
o
Brazil
·
MEA
o
South Africa
